Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 31%
Sell 15%
Strong Sell 0%

Bulls say

CME Group is projected to experience a potential earnings boost of approximately 4% to 5%, primarily driven by its partnership with FanDuel, which may contribute around $300 million at an estimated 80% pre-tax margin, translating to an incremental EPS of about $0.52. Furthermore, the company is poised for significant customer expansion opportunities, with revenue potential exceeding $300 million annually should its offerings achieve volumes comparable to successful partnerships like HOOD-Kalshi. These factors, coupled with a positive outlook regarding prediction markets, have led to an increase in projected EPS estimates, underscoring the robust growth potential for CME Group in the coming years.

Bears say

CME Group faces significant regulatory risk, as potential increases in margin requirements, speculation limitations, and restrictions on high-frequency trading could lead to decreased trading volumes in the U.S. The firm also confronts challenges related to industry fundamentals, with changing customer demand and product pricing potentially negatively impacting revenues and earnings, alongside competitive pressures that may alter investor perceptions of the company and its sector. Additionally, the exposure to substantial credit risk from third-party clearing operations raises concerns about the stability of CME's working capital, especially in light of recent regulatory developments affecting related markets.

CME Group (CME) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 15% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 13 analysts, CME Group (CME) has a Buy consensus rating as of Feb 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $288, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $288, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.